全文获取类型
收费全文 | 35997篇 |
免费 | 1724篇 |
国内免费 | 295篇 |
专业分类
耳鼻咽喉 | 266篇 |
儿科学 | 682篇 |
妇产科学 | 413篇 |
基础医学 | 4786篇 |
口腔科学 | 1002篇 |
临床医学 | 2109篇 |
内科学 | 8972篇 |
皮肤病学 | 855篇 |
神经病学 | 2455篇 |
特种医学 | 1253篇 |
外科学 | 6478篇 |
综合类 | 144篇 |
一般理论 | 1篇 |
预防医学 | 989篇 |
眼科学 | 630篇 |
药学 | 2085篇 |
中国医学 | 123篇 |
肿瘤学 | 4773篇 |
出版年
2024年 | 24篇 |
2023年 | 202篇 |
2022年 | 537篇 |
2021年 | 881篇 |
2020年 | 451篇 |
2019年 | 648篇 |
2018年 | 849篇 |
2017年 | 662篇 |
2016年 | 779篇 |
2015年 | 811篇 |
2014年 | 1081篇 |
2013年 | 1372篇 |
2012年 | 2238篇 |
2011年 | 2621篇 |
2010年 | 1475篇 |
2009年 | 1215篇 |
2008年 | 2232篇 |
2007年 | 2468篇 |
2006年 | 2309篇 |
2005年 | 2483篇 |
2004年 | 2397篇 |
2003年 | 2396篇 |
2002年 | 2401篇 |
2001年 | 361篇 |
2000年 | 304篇 |
1999年 | 432篇 |
1998年 | 575篇 |
1997年 | 454篇 |
1996年 | 431篇 |
1995年 | 371篇 |
1994年 | 325篇 |
1993年 | 297篇 |
1992年 | 214篇 |
1991年 | 187篇 |
1990年 | 183篇 |
1989年 | 165篇 |
1988年 | 148篇 |
1987年 | 108篇 |
1986年 | 100篇 |
1985年 | 88篇 |
1984年 | 104篇 |
1983年 | 85篇 |
1982年 | 71篇 |
1981年 | 87篇 |
1980年 | 82篇 |
1979年 | 59篇 |
1978年 | 41篇 |
1977年 | 29篇 |
1976年 | 24篇 |
1975年 | 23篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
991.
Michinori Ogura Kiyoshi Ando Tatsuya Suzuki Kenichi Ishizawa Sung Yong Oh Kuniaki Itoh Kazuhito Yamamoto Wing Yan Au Hwei‐Fang Tien Yoshihiro Matsuno Takashi Terauchi Keiko Yamamoto Masahiko Mori Yoshinobu Tanaka Takashi Shimamoto Kensei Tobinai Won Seog Kim 《British journal of haematology》2014,165(6):768-776
Although initial rituximab‐containing chemotherapies achieve high response rates, indolent B‐cell non‐Hodgkin lymphoma (B‐NHL), such as follicular lymphoma (FL), is still incurable. Therefore, new effective agents with novel mechanisms are anticipated. In this multicentre phase II study, patients with relapsed/refractory indolent B‐NHL and mantle cell lymphoma (MCL) received vorinostat 200 mg twice daily for 14 consecutive days in a 21‐d cycle until disease progression or unacceptable toxicity occurred. The primary endpoint was overall response rate (ORR) in FL patients and safety and tolerability in all patients. Secondary endpoints included progression‐free survival (PFS). Fifty‐six eligible patients were enrolled; 50 patients (39 with FL, seven with other B‐NHL, and four with MCL) were evaluable for ORR, and 40 patients had received rituximab‐containing prior chemotherapeutic regimens. For the 39 patients with FL, the ORR was 49% [95% confidence interval (CI): 32·4, 65·2] and the median PFS was 20 months (95% CI: 11·2, 29·7). Major toxicities were manageable grade 3/4 thrombocytopenia and neutropenia. Vorinostat offers sustained antitumour activity in patients with relapsed or refractory FL with an acceptable safety profile. Further investigation of vorinostat for clinical efficacy is warranted. 相似文献
992.
Sari ImamuraKumiko Hirata MD PhD Makoto OriiKunihiro Shimamura MD Yasutsugu ShionoKohei Ishibashi MD PhD Takashi TanimotoTakashi Yamano MD PhD Yasushi InoHironori Kitabata MD PhD Tomoyuki YamaguchiTakashi Kubo MD PhD Atsushi TanakaToshio Imanishi MD PhD Takashi Akasaka MD PhD 《The American journal of cardiology》2014
993.
994.
Honda Mika Iida Takashi Kamiyama Hirona Masuda Manabu Kawara Misao Svensson Peter Komiyama Osamu 《Clinical oral investigations》2019,23(2):757-762
Clinical Oral Investigations - The aim of this study was to compare mechanical sensitivity on the tongue using quantitative sensory testing (QST) and psychological factors using the General Health... 相似文献
995.
Masahiro Nakamura Noriaki Kawanabe Rie Adachi Takashi Yamashiro Hiroshi Kamioka 《The Angle orthodontist》2019,89(2):333
This report illustrates successful nonsurgical orthodontic treatment of a hypodivergent adult patient with bilateral posterior scissors bite (Brodie bite) and excessive overjet. A 26-year-old woman primarily reported maxillary incisor protrusion. She was diagnosed with Class ll division 1 malocclusion with skeletal Class I, short face, low mandibular plane angle and bilateral posterior scissors bite. A lingual arch with anterior bite block and posterior miniscrews with preadjusted edgewise appliances were used to improve the bilateral scissors bite. After achieving molar occlusion, the maxillary first premolars were extracted, and six miniscrews were used to improve the anterior-posterior and vertical discrepancies. After active treatment for 56 months, the convex facial profile with excessively protruded lips was improved and good interdigitation with ideal incisor relationship was achieved. Additionally, the irregular movements of the incisal path and the bilateral condyles during lateral excursion were improved. At 13 months of retention, a satisfactory facial profile, occlusion, and jaw movements were maintained. The treatment results suggest that miniscrews and fixed bite blocks were effective and efficient to facilitate correction of the bilateral scissors bite, excessive overjet, and vertical relationship correction in this nonsurgical orthodontic treatment. 相似文献
996.
Takehiro Igarashi Takashi Kambe Hitoshi Kihara 《Journal of labelled compounds & radiopharmaceuticals》2019,62(12):865-869
18O‐labeled water (Water‐18O) is a widely used starting material of 18F‐labeled diagnostic agents in positron emission tomography (PET). Conventionally, Water‐18O has been separated from other stable oxygen isotope species (16O, 17O) by water distillation or nitric oxide distillation. However, conventional methods are costly and may have safety issues. In 2004, we developed the first unit of our novel oxygen isotope separation process by cryogenic oxygen distillation to overcome these issues. To meet the needs of the market, we built a second unit in 2013 and a third in 2016. We are now operating three commercially viable separation units with a total capacity of 600 kg of Water‐18O per year. 相似文献
997.
998.
999.
Keiji Isshiki Toshiki Nishio Motohide Isono Tetsuya Makiishi Tsutomu Shikano Koubin Tomita Toshiji Nishio Masami Kanasaki Hiroshi Maegawa Takashi Uzu 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2014,18(5):434-442
Glycated albumin (GA) is considered a more reliable marker than glycated hemoglobin (HbA1c) for monitoring glycemic control, particularly in diabetic hemodialysis patients. We investigated the associations of GA, HbA1c, and random serum glucose levels with survival, and evaluated possible targets for improving survival in diabetic hemodialysis patients. In this prospective, longitudinal, observational study, we enrolled 90 diabetic hemodialysis patients across six dialysis centers in Japan. The median duration of follow‐up was 36.0 months (mean follow‐up, 29.8 months; range, 3–36 months). There were 11 deaths during the observation period. GA was a significant predictor for mortality (hazard ratio, 1.143 per 1% increase in GA; 95% confidence interval, 1.011–1.292; P = 0.033), whereas HbA1c and random glucose levels were not predictors for mortality. Receiver operating characteristics curve analysis showed that the cutoff value of GA for predicting the risk of mortality was 25%. In the Kaplan–Meier analysis, the cumulative survival rate was significantly greater in patients with GA ≤25% than in patients with GA >25%. GA predicted the risk of all‐cause and cardiovascular mortality in diabetic hemodialysis patients. Our results suggest that GA ≤25% is an appropriate target for improving survival in diabetic hemodialysis patients. 相似文献
1000.
Tadao Akizawa Akira Saito Fumitake Gejyo Masashi Suzuki Yoshiki Nishizawa Yasuhiko Tomino Yoshiharu Tsubakihara Takashi Akiba Hideki Hirakata Yuzo Watanabe Hideki Kawanishi Masami Bessho Yukio Udagawa Kotonari Aoki Yukari Uemura Yasuo Ohashi Co‐JET Study Group 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2014,18(2):140-148
The effect of recombinant human erythropoietin (rHuEPO) treatment on the progression of chronic kidney disease (CKD) has not been fully evaluated in Japan. We therefore retrospectively evaluated this in a sub‐cohort of a prospective multicenter study to investigate optimal hemoglobin (Hb) level of CKD patients on hemodialysis (HD) treated with rHuEPO; Japan Erythropoietin Treatment Study for Target Hb and Survival (JET study). Effect of rHuEPO treatment during predialysis period to delay initiation of HD was retrospectively assessed in 2434 patients from the JET study comparing groups with and without rHuEPO treatment. The assessment was done by Cox proportional hazards regression analysis and inverse probability‐weighted (IPW) analysis to adjust for time‐dependent confounders. The weights used in the IPW analysis were calculated using a logistic model that included baseline confounders and time‐dependent variables. During the predialysis period, 71.7% (1746 patients) were treated with rHuEPO (mean Hb level of 8.7 g/dL at initiation of rHuEPO treatment). Covariates significantly associated with initiation of rHuEPO treatment were Hb level, serum creatinine level, age, diabetes, cardiac insufficiency, and hypertension. The adjusted hazard ratio for time until HD initiation under rHuEPO treatment was 0.272 (95% CI, 0.223–0.331; P < 0.001) in the Cox analysis and 0.63 (95% CI, 0.53–0.76; P < 0.0001) in the IPW analysis. This retrospective study suggests that rHuEPO treatment during the predialysis period has preventive effects on the progression of CKD although further prospective investigation on the efficacy is needed. 相似文献